Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	28.68	15.36	90.54	105.14	71.9
Short-Term Investments	51.73	69.49	67.04	103.35	319.07
Cash & Cash Equivalents	80.41	84.85	157.58	208.49	390.97
Cash Growth	-5.24%	-46.15%	-24.42%	-46.67%	17.63%
Receivables	60.14	52.05	35.5	41.85	39.88
Inventory	42.11	54.57	48.38	41.91	24.97
Other Current Assets	6.12	13.96	12.96	21.95	23.25
Total Current Assets	188.77	205.44	254.42	314.2	479.06
Property, Plant & Equipment	25.6	29.81	33.56	39.01	33.37
Other Long-Term Assets	8.13	15.71	17.72	0.35	0.35
Total Long-Term Assets	33.73	45.52	51.28	39.36	33.72
Total Assets	222.51	250.95	305.71	353.56	512.78
Accounts Payable	3.24	3.23	3.8	0.53	2.76
Current Debt	3.08	2.69	2.42	10.05	7.55
Other Current Liabilities	73.37	76.44	64.84	91.93	86.4
Total Current Liabilities	79.69	82.36	71.06	102.5	96.71
Long-Term Debt	176.55	154.78	157.08	14.56	12.24
Other Long-Term Liabilities	0.24	0.24	0	0	0
Total Long-Term Liabilities	176.79	155.02	157.08	14.56	12.24
Total Liabilities	256.48	237.38	228.14	117.06	108.95
Total Debt	179.63	157.48	159.5	24.61	19.79
Debt Growth	14.07%	-1.27%	548.06%	24.35%	332.71%
Retained Earnings	-1,906.01	-1,795.46	-1,613.43	-1,392.75	-1,165.47
Comprehensive Income	0.01	-0.02	-0.01	0.26	0.09
Shareholders' Equity	-33.97	13.57	77.57	236.49	403.84
Net Cash / Debt	-99.22	-72.63	-1.92	183.88	371.18
Net Cash / Debt Growth	-	-	-	-50.46%	13.23%
Net Cash Per Share	-0.72	-0.67	-0.02	2.03	4.54
Working Capital	109.09	123.08	183.37	211.69	382.36
Book Value Per Share	-0.25	0.13	0.79	2.60	4.94

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).